FOLH1 and neoplasm: Later, some second-generation 18F-labeled PSMA ligands were introduced to overcome the high blood-pool activity and low tumor-to-background ratios of 18F-DCFBC, namely, 18F-DCFPyL and, more recently, 18F-PSMA-1007, which has very low urine clearance 3,9.